## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.8% below STRENGTH zone (3.0-6.0%); PEG 1.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($12.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation**
- Source: CBS 17 | 20251216T210931 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (NASDAQ:ACHC) on behalf of investors. The investigation follows Acadia's disclosure of higher anticipated patient-related litigation costs, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance. Investors who purchased Acadia securities are encouraged to contact the law firm to learn more about the ongoing investigation.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: KLBK | 20251216T160839 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to join the investigation. Interested investors can find more information or assist by visiting bgandg.com/ACHC.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $17 | $22 | -23% |
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 36.2% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (10 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.3 |
| Current P/E | 6.9 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -2.8% to 1.8% (+4.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Below SMA200 (0.64x), long-term trend not supportive. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.77% (CS: 63) | Neutral |
| RSI_14 | 36.7 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 0.955x | Below |
| vs SMA50 | 0.769x | Below |
| vs SMA200 | 0.638x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.43
- **Stop Loss:** $12.63 (12.5% risk)
- **Target:** $16.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 527
- **Position Value:** $7,604.61
- **Portfolio %:** 7.60%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*